Children’s Cancer Cause gives 2026 Rosen Award to Dr. Gregory Reaman
Children’s Cancer Cause honored pediatric oncologist Gregory Reaman with its 2026 Leonard M. Rosen Memorial Research Award at a Nov. 5 event in New York City. The award recognizes his leadership in childhood cancer research, drug development, data sharing and advocacy for patients and families.
Why it matters: - Dr. Gregory Reaman’s work has shaped pediatric cancer research, drug development and patient care across federal agencies, hospitals and advocacy efforts. - The award highlights the growing importance of data sharing, survivorship research and family advocacy in childhood cancer. - Children’s Cancer Cause says the recognition also reflects Reaman’s commitment to the nation’s more than 521,000 childhood cancer survivors.
What happened: - Children’s Cancer Cause presented Gregory Reaman, MD, with the 2026 Leonard M. Rosen Memorial Research Award. - Adam L. Rosen, chair of the Children’s Cancer Cause board of directors, presented the award at the nonprofit’s annual fundraising event on Nov. 5 in New York City. - The nonprofit announced the honor on Nov. 17, 2026.
The details: - The Rosen Award was established in 2016 to honor people whose work in childhood cancer policy, advocacy and research addresses the needs of young patients, families and survivors. - The award honors Leonard M. Rosen, a founding board member and former chair of Children’s Cancer Cause. - Reaman was the founding chair of the Children’s Oncology Group. - Reaman specializes in acute leukemia and drug development. - Reaman has authored more than 400 peer-reviewed publications. - Reaman served as executive director of the Center for Cancer and Blood Disorders at Children’s National Hospital for 18 years. - Reaman is professor emeritus of pediatrics at George Washington University School of Medicine. - Reaman later served as associate director for pediatric oncology in the FDA’s Oncology Center of Excellence and associate director for pediatrics in the Office of Oncologic Diseases. - Reaman most recently served as scientific director of the National Cancer Institute’s Childhood Cancer Data Initiative before retirement. - Reaman continues as a special volunteer and advisor for clinical translation to the Childhood Cancer Data Initiative, which aims to expand data sharing and help researchers learn from every child with cancer. - Reaman has been a member of the Children’s Cancer Cause board for more than five years.
Between the lines: - The award signals that childhood cancer progress depends on more than laboratory research. It also depends on federal policy, clinical translation and better ways to turn patient data into usable research. - Rosen’s remarks suggest advocacy groups see Reaman as a bridge between researchers, regulators and families. - Reaman’s career reflects a shift in pediatric oncology toward long-term survivorship and collaboration across institutions.
What’s next: - Children’s Cancer Cause directs readers to more information about the award and past recipients at the Rosen Award page. - Reaman will remain involved as an advisor to the Childhood Cancer Data Initiative after retirement. - Children’s Cancer Cause says it will continue promoting policies and programs aimed at safer, more effective pediatric cancer therapies and better survivorship support.
The bottom line: - The 2026 Rosen Award places Dr. Gregory Reaman among the most influential figures in pediatric oncology and underscores the field’s push to improve both treatment and long-term outcomes for children with cancer.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Tech Times of New York
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.